Liftstream is an executive search recruitment company in the life sciences sector
Editas Medicine Appoints John D. Mendlein to Board of Directors
Editas Medicine, a genome editing company based in Cambridge, Mass, has appointed John D. Mendlein to its board of directors. Mendlein has served as CEO of aTyr Pharma since 2011, as well as executive chairman for the company from July 2010 to January 2016.
China’s Simcere Plans Hong Kong IPO
Simcere Pharmaceutical Group, based in Jiangsu province, China, is preparing to raise as much as USD1 billion in a Hong Kong IPO in the third quarter, according to The Wall Street Journal. The firm did not release any official statement regarding the possible plan.
Kite Pharma Shows Positive results from non-Hodgkin lymphoma study
Authored by James Sheppard
Avalanche Biotechnologies raises $102m in up-sized IPO
Authored by James Sheppard
Rare Disease biotech Aldeyra raises $25m in IPO
Authored by James Sheppard
CFO appointments no longer just a numbers game
Authored by Karl Simpson
Posted in General, Pharmaceutical business, Recruitment Market
Tagged Asia, AstraZeneca, biotechnology, board, CEO, CFO, Chairman, europe, external communication, financial technocrats, globalising, IPO, Liftstream, management, Marc Dunoyer, Pascal Soriot, private biotechs, public company, Rare Disease, regulatory, venture capital
Leave a comment
Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Amsterdam Biotech, Ataluren, Charity, clinical, DART Therapeutics, DMD, Drisapersen, Duchenne Muscular Dystrophy, Eteplirsen, FDA, Gene Williams, Glynn Edwards, GSK, GSK/Prosensa, HT-100, IPO, Market Access, NASDAQ, Netherlands, Orphan drugs, Oxford Biotech, phase II studies, Priority Review, Prosensa, PTC Therapeutics, Rare Disease, regulatory affairs, research and development, Sarepta Therapeutics, Save our Sons, SMT C1100, Summit plc, UK, USA, Utrophin, utrophin modulation
2 Comments